CNS Pharmaceuticals Files S-1/A Amendment

TL;DR

<b>CNS Pharmaceuticals, Inc. has filed an S-1/A amendment, providing updated financial and business information.</b>

AI Summary

CNS Pharmaceuticals, Inc. (CNSP) filed a Amended IPO Registration (S-1/A) with the SEC on January 22, 2024. CNS Pharmaceuticals, Inc. filed an S-1/A amendment on January 22, 2024. The filing relates to the Securities Act of 1933. The company's principal executive offices are located in Houston, TX. The filing includes data for the fiscal year ending December 31, 2023, and comparative periods. The SIC code for the company is 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking CNS Pharmaceuticals, Inc., this filing contains several important signals. This amendment updates the company's registration statement, which is crucial for potential future stock offerings or other capital-raising activities. The filing provides a snapshot of the company's financial position and operational details as of late 2023, offering insights into its current status.

Risk Assessment

Risk Level: low — CNS Pharmaceuticals, Inc. shows low risk based on this filing. The risk is low as this is a routine S-1/A filing for informational purposes and does not indicate immediate financial distress or significant new risks.

Analyst Insight

Monitor future filings for updates on the company's strategic initiatives and financial performance following this amendment.

Key Numbers

• 2023-09-30 — Most Recent Quarter End Date (Financial reporting period)
• 2022-12-31 — Prior Year End Date (Financial reporting period)
• 2023-01-01 — Start of Current Reporting Period (Financial reporting period)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — Filer name
• 2024-01-22 (date) — Filing date
• 1933 Act (regulatory) — SEC Act
• Houston, TX (location) — Business address
• 2834 (industry_code) — Standard Industrial Classification

Forward-Looking Statements

• CNS Pharmaceuticals will likely proceed with a public offering of securities in the near future. (CNS Pharmaceuticals, Inc.) — medium confidence, target: 2024-06-30

FAQ

Industry Context

CNS Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of novel treatments.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial statements and business descriptions.
2. Track future SEC filings from CNS Pharmaceuticals for any significant updates.
3. Analyze the company's strategic direction and product pipeline based on information within the filing.

Key Dates

• 2024-01-22: S-1/A Filing — Amendment to registration statement

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updates or additions to the initial registration statement.

Key Financial Figures

• $0.6935 — sumed combined public offering price of $0.6935 per share and accompanying common warra
• $0.001 — mmon stock and has an exercise price of $0.001 per share. The combined purchase price
• $0 — ccompanying common warrants is equal to $0.6925, which is equal to the combined pu
• $750,000 — eed to pay HPI: (i) development fees of $750,000 over a three-year period beginning Nove
• $50,000 — (ii) a 2% royalty on net sales; (iii) a $50,000 per year license fee; (iv) milestone pa
• $100,000 — license fee; (iv) milestone payments of $100,000 upon the commencement of a Phase II tri
• $1.0 million — he commencement of a Phase II trial and $1.0 million upon the approval of a New Drug Applica
• $1,134,000 — ancies. We agreed to fund approximately $1,134,000 over a two-year period. We paid and rec
• $334,000 — a two-year period. We paid and recorded $334,000 in 2020 related to this agreement in re
• $800,000 — statements of operations. The remaining $800,000 was paid in 2021. The principal investi
• $1.28 — hares of the Company's common stock, at $1.28 per share, in exchange for the Company'

Filing Documents

• cnspharma_s1a2.htm (S-1/A) — 1383KB
• cnspharma_ex0411.htm (EX-4.11) — 106KB
• cnspharma_ex0412.htm (EX-4.12) — 108KB
• cnspharma_ex0501.htm (EX-5.1) — 15KB
• cnspharma_ex1022.htm (EX-10.22) — 277KB
• cnspharma_ex2301.htm (EX-23.1) — 2KB
• cnspharma_ex107.htm (EX-FILING FEES) — 33KB
• arent_logo.jpg (GRAPHIC) — 6KB
• 0001683168-24-000358.txt (&nbsp;) — 4390KB
• cnsp-20230930.xsd (EX-101.SCH) — 19KB
• cnsp-20230930_cal.xml (EX-101.CAL) — 25KB
• cnsp-20230930_def.xml (EX-101.DEF) — 106KB
• cnsp-20230930_lab.xml (EX-101.LAB) — 204KB
• cnsp-20230930_pre.xml (EX-101.PRE) — 172KB
• cnspharma_s1a2_htm.xml (XML) — 271KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 24

DILUTION

DILUTION 26 CAPITALIZATION 28

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29

BUSINESS

BUSINESS 33 MANAGEMENT 49 EXECUTIVE AND DIRECTOR COMPENSATION 52 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 56

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 58

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 59 DESCRIPTION OF PRE-FUNDED WARRANTS 62 DESCRIPTION OF COMMON WARRANTS 63 PLAN OF DISTRIBUTION 66 LEGAL MATTERS 68 EXPERTS 68 WHERE YOU CAN FIND MORE INFORMATION 69 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC to register the securities offered hereby under the Securities Act. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. You should carefully read this prospectus before deciding to invest in our securities. We have not, and the placement agents have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the placement agents have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions r

View Full Filing

View this S-1/A filing on SEC EDGAR